Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels

Journal of Biological Chemistry

Volumn 287, Issue 52, 2012, Pages 43482-43491

  Lipari, Michael T ^a   Li, Wei ^a   Moran, Paul ^a   Kong Beltran, Monica ^a   Sai, Tao ^a   Lai, Joyce ^a   Lin, S Jack ^a   Kolumam, Ganesh ^a   Zavala Solorio, Jose ^a   Izrael Tomasevic, Anita ^a   Arnott, David ^a   Wang, Jianyong ^a   Peterson, Andrew S ^a   Kirchhofer, Daniel ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING DATA; CATALYTIC DOMAINS; HEPG2 CELLS; LDL CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTORS; MOUSE LIVER; N-TERMINALS; RECEPTOR LEVELS; SERUM CHOLESTEROL; SUBTILISIN;

MASS SPECTROMETRY;

BODY FLUIDS;

CHOLESTEROL; FURIN; HEPSIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL STRAIN HEPG2; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GEL PERMEATION CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHOLESTEROL; FURIN; HEP G2 CELLS; HUMANS; LIVER; MICE; MICE, KNOCKOUT; PROPROTEIN CONVERTASES; PROTEIN STRUCTURE, SECONDARY; PROTEOLYSIS; RECEPTORS, LDL; SERINE ENDOPEPTIDASES;

MUS;

EID: 84871587036     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.380618     Document Type: Article

References (39)

1. Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2009) PCSK9. A convertase that coordinates LDL catabolism. J. Lipid Res. 50, (suppl.) S172-177
2. Seidah, N. G. (2009) PCSK9 as a therapeutic target of dyslipidemia. Expert. Opin. Ther. Targets 13, 19-28
3. Costet, P., Krempf, M., and Cariou, B. (2008) PCSK9 and LDL cholesterol. Unravelling the target to design the bullet. Trends Biochem. Sci. 33, 426-434
4. Duff, C. J., and Hooper, N. M. (2011) PCSK9. An emerging target for treatment of hypercholesterolemia. Expert. Opin. Ther. Targets 15, 157-168
5. Cohen, J. C., Boerwinkle, E., Mosley, T. H., Jr., and Hobbs, H. H. (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272
6. Cunningham, D., Danley, D. E., Geoghegan, K. F., Griffor, M. C., Hawkins, J. L., Subashi, T. A., Varghese, A. H., Ammirati, M. J., Culp, J. S., Hoth, L. R., Mansour, M. N., McGrath, K. M., Seddon, A. P., Shenolikar, S., Stutzman-Engwall, K. J., Warren, L. C., Xia, D., and Qiu, X. (2007) Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 14, 413-419 (Pubitemid 46685885)
7. Hampton, E. N., Knuth, M. W., Li, J., Harris, J. L., Lesley, S. A., and Spraggon, G. (2007) The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc. Natl. Acad. Sci. U.S.A. 104, 14604-14609 (Pubitemid 350003191)
8. Piper, D. E., Jackson, S., Liu, Q., Romanow, W. G., Shetterly, S., Thibault, S. T., Shan, B., and Walker, N. P. (2007) The crystal structure of PCSK9. A regulator of plasma LDL-cholesterol. Structure 15, 545-552 (Pubitemid 46702689)
9. Kwon, H. J., Lagace, T. A., McNutt, M. C., Horton, J. D., and Deisenhofer, J. (2008) Molecular basis for LDL receptor recognition by PCSK9. Proc. Natl. Acad. Sci. U.S.A. 105, 1820-1825 (Pubitemid 351439423)
10. Zhang, D. W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2007) Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282, 18602-18612 (Pubitemid 47100234)
11. Malby, S., Pickering, R., Saha, S., Smallridge, R., Linse, S., and Downing, A. K. (2001) The first epidermal growth factor-like domain of the low-density lipoprotein receptor contains a noncanonical calcium binding site. Biochemistry 40, 2555-2563 (Pubitemid 32171730)
12. McNutt, M. C., Lagace, T. A., and Horton, J. D. (2007) Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J. Biol. Chem. 282, 20799-20803 (Pubitemid 47099894)
13. Li, J., Tumanut, C., Gavigan, J. A., Huang, W. J., Hampton, E. N., Tumanut, R., Suen, K. F., Trauger, J. W., Spraggon, G., Lesley, S. A., Liau, G., Yowe, D., and Harris, J. L. (2007) Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem. J. 406, 203-207 (Pubitemid 47310950)
14. Ni, Y. G., Condra, J. H., Orsatti, L., Shen, X., Di Marco, S., Pandit, S., Bottomley, M. J., Ruggeri, L., Cummings, R. T., Cubbon, R. M., Santoro, J. C., Ehrhardt, A., Lewis, D., Fisher, T. S., Ha, S., Njimoluh, L., Wood, D. D., Hammond, H. A., Wisniewski, D., Volpari, C., Noto, A., Lo Surdo, P., Hubbard, B., Carfí, A., and Sitlani, A. (2010) A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J. Biol. Chem. 285, 12882-12891
15. Mayer, G., Poirier, S., and Seidah, N. G. (2008) Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J. Biol. Chem. 283, 31791-31801
16. Yamamoto, T., Lu, C., and Ryan, R. O. (2011) A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor. J. Biol. Chem. 286, 5464-5470
17. Holla, Ø. L., Cameron, J., Tveten, K., Strøm, T. B., Berge, K. E., Laerdahl, J. K., and Leren, T. P. (2011) Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors. J. Lipid Res. 52, 1787-1794
18. Benjannet, S., Rhainds, D., Hamelin, J., Nassoury, N., and Seidah, N. G. (2006) The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A. Functional consequences of natural mutations and posttranslational modifications. J. Biol. Chem. 281, 30561-30572 (Pubitemid 44582112)
19. Essalmani, R., Susan-Resiga, D., Chamberland, A., Abifadel, M., Creemers, J. W., Boileau, C., Seidah, N. G., and Prat, A. (2011) In vivo evidence that furin from hepatocytes inactivates PCSK9. J. Biol. Chem. 286, 4257-4263
20. Dubuc, G., Tremblay, M., Paré, G., Jacques, H., Hamelin, J., Benjannet, S., Boulet, L., Genest, J., Bernier, L., Seidah, N. G., and Davignon, J. (2010) A new method for measurement of total plasma PCSK9. Clinical applications. J. Lipid Res. 51, 140-149
21. Troutt, J. S., Alborn, W. E., Cao, G., and Konrad, R. J. (2010) Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J. Lipid Res. 51, 345-351
22. Zaid, A., Roubtsova, A., Essalmani, R., Marcinkiewicz, J., Chamberland, A., Hamelin, J., Tremblay, M., Jacques, H., Jin, W., Davignon, J., Seidah, N. G., and Prat, A. (2008) Proprotein convertase subtilisin/kexin type 9 (PCSK9). Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 48, 646-654
23. Cameron, J., Holla, O. L., Laerdahl, J. K., Kulseth, M. A., Ranheim, T., Rognes, T., Berge, K. E., and Leren, T. P. (2008) Characterization of novel mutations in the catalytic domain of the PCSK9 gene. J. Intern. Med. 263, 420-431 (Pubitemid 351342682)
24. Abifadel, M., Varret, M., Rabès, J. P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J. M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., and Boileau, C. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156 (Pubitemid 36666925)
25. Allard, D., Amsellem, S., Abifadel, M., Trillard, M., Devillers, M., Luc, G., Krempf, M., Reznik, Y., Girardet, J. P., Fredenrich, A., Junien, C., Varret, M., Boileau, C., Benlian, P., and Rabes, J. P. (2005) Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum. Mutat. 26, 497
26. Ganesan, R., Zhang, Y., Landgraf, K. E., Lin, S. J., Moran, P., and Kirchhofer, D. (2012) An allosteric anti-hepsin antibody derived from a constrained phage display library. Protein Eng. Des. Sel. 25, 127-133
27. Kirchhofer, D., Peek, M., Li, W., Stamos, J., Eigenbrot, C., Kadkhodayan, S., Elliott, J. M., Corpuz, R. T., Lazarus, R. A., and Moran, P. (2003) Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J. Biol. Chem. 278, 36341-36349 (Pubitemid 37139961)
28. Lo Surdo, P., Bottomley, M. J., Calzetta, A., Settembre, E. C., Cirillo, A., Pandit, S., Ni, Y. G., Hubbard, B., Sitlani, A., and Carfí, A. (2011) Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep. 12, 1300-1305
29. Schechter, I., and Berger, A. (1967) On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27, 157-162
30. Fisher, T. S., Lo Surdo, P., Pandit, S., Mattu, M., Santoro, J. C., Wisniewski, D., Cummings, R. T., Calzetta, A., Cubbon, R. M., Fischer, P. A., Tarachandani, A., De Francesco, R., Wright, S. D., Sparrow, C. P., Carfi, A., and Sitlani, A. (2007) Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J. Biol. Chem. 282, 20502-20512 (Pubitemid 47100016)
31. Chan, J. C., Piper, D. E., Cao, Q., Liu, D., King, C., Wang, W., Tang, J., Liu, Q., Higbee, J., Xia, Z., Di, Y., Shetterly, S., Arimura, Z., Salomonis, H., Romanow, W. G., Thibault, S. T., Zhang, R., Cao, P., Yang, X. P., Yu, T., Lu, M., Retter, M. W., Kwon, G., Henne, K., Pan, O., Tsai, M. M., Fuchslocher, B., Yang, E., Zhou, L., Lee, K. J., Daris, M., Sheng, J., Wang, Y., Shen, W. D., Yeh, W. C., Emery, M., Walker, N. P., Shan, B., Schwarz, M., and Jackson, S. M. (2009) A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. U.S.A. 106, 9820-9825
32. Liang, H., Chaparro-Riggers, J., Strop, P., Geng, T., Sutton, J. E., Tsai, D., Bai, L., Abdiche, Y., Dilley, J., Yu, J., Wu, S., Chin, S. M., Lee, N. A., Rossi, A., Lin, J. C., Rajpal, A., Pons, J., and Shelton, D. L. (2012) Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J. Pharmacol. Exp. Ther. 340, 228-236
33. Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., Du, Y., Kranz, T., Gasparino, E., and Swergold, G. D. (2012) Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366, 1108-1118
34. Krissinel, E., and Henrick, K. (2007) Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774-797 (Pubitemid 47321791)
35. Duff, C. J., Scott, M. J., Kirby, I. T., Hutchinson, S. E., Martin, S. L., and Hooper, N. M. (2009) Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem. J. 419, 577-584
36. Guipponi, M., Tan, J., Cannon, P. Z., Donley, L., Crewther, P., Clarke, M., Wu, Q., Shepherd, R. K., and Scott, H. S. (2007) Mice deficient for the type II transmembrane serine protease, TMPRSS1/hepsin, exhibit profound hearing loss. Am. J. Pathol. 171, 608-616 (Pubitemid 47344693)
37. Magee, J. A., Araki, T., Patil, S., Ehrig, T., True, L., Humphrey, P. A., Catalona, W.J., Watson, M. A., and Milbrandt, J. (2001) Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 61, 5692-5696 (Pubitemid 32769078)
38. Klezovitch, O., Chevillet, J., Mirosevich, J., Roberts, R. L., Matusik, R. J., and Vasioukhin, V. (2004) Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 6, 185-195 (Pubitemid 39485690)
39. Li, W., Wang, B. E., Moran, P., Lipari, T., Ganesan, R., Corpuz, R., Ludlam, M. J., Gogineni, A., Koeppen, H., Bunting, S., Gao, W. Q., and Kirchhofer, D. (2009) Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis. Cancer Res. 69, 8395-8402